

Contains Nonbinding Recommendations

Draft Guidance on Nicotine Polacrilex

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Nicotine Polacrilex

Form/Route: Lozenge/Oral

Recommended studies: 1 study

Type of study: Fasting

Design: Single-dose, two-way crossover in-vivo

Strength: Eq. 4 mg base

Subjects: Healthy males and nonpregnant females, general population.

Additional Comments:

Analytes to measure (in appropriate biological fluid): Nicotine in plasma

Bioequivalence based on (90% CI): Nicotine

Waiver request of in-vivo testing: Eq. 2 mg based on (i) acceptable bioequivalence study on the Eq. 4 mg base strength, (ii) acceptable in-vitro dissolution testing on all strengths, and (iii) proportional similarity of the formulation across all strengths. Please refer to the Mirtazapine Tablet Draft Guidance for additional information regarding waivers of in-vivo testing.

Lozenges with alternate flavors can not be filed in the same ANDA as the mint flavored lozenge. For each flavor, a separate submission (ANDA) should be submitted.

Lozenges with an alternate flavor may be eligible for a waiver of the bioequivalence study requirements based on (1) an acceptable bioequivalence study on the 4 mg strength of the mint lozenge, (2) acceptable dissolution testing for the nicotine polacrilex lozenge with additional flavor vs. the RLD, (3) proportional similarity in the formulations of the nicotine polacrilex lozenge with additional flavor and nicotine polacrilex lozenge with mint flavor, and (4) the additional flavor (the inactives) has been approved for the same route of administration.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Data** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.